On November 27, 2024, Justin Chakma, Chief Business Officer at ARS Pharmaceuticals Inc (SPRY, Financial), sold 100,000 shares of the company. Following this transaction, the insider now owns 136,380 shares of the company. The details of this transaction can be found in the SEC Filing.
ARS Pharmaceuticals Inc (SPRY) is a biopharmaceutical company focused on developing novel therapies for the treatment of severe allergic reactions. The company aims to provide innovative solutions to improve patient outcomes in emergency situations.
The insider transaction history for ARS Pharmaceuticals Inc shows a trend of insider selling. Over the past year, there have been 52 insider sells and only 1 insider buy. This recent sale by Justin Chakma is part of this broader trend.
On the day of the transaction, shares of ARS Pharmaceuticals Inc were trading at $14.12 each, giving the stock a market cap of $1.412 billion.
For investors and analysts, it is important to consider various valuation metrics such as the GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow to assess the stock's potential and make informed decisions.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
